Anixa Biosciences, Inc.

NasdaqCM:ANIX 주식 리포트

시가총액: US$93.5m

Anixa Biosciences 경영진

경영진 기준 점검 3/4

Anixa Biosciences CEO는 Amit Kumar, Jul2017 에 임명되었습니다 의 임기는 8.83 년입니다. 총 연간 보상은 $2.55M, 32% 급여 및 68% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $1.70M 가치에 해당하는 회사 주식의 1.82% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 8.8 년과 7.6 년입니다.

핵심 정보

Amit Kumar

최고경영자

US$2.5m

총 보수

CEO 급여 비율32.01%
CEO 재임 기간8.8yrs
CEO 지분 보유율1.8%
경영진 평균 재임 기간8.8yrs
이사회 평균 재임 기간7.6yrs

최근 경영진 업데이트

Recent updates

분석 기사 • Mar 25

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 19

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 40%?

Key Insights The projected fair value for Anixa Biosciences is US$4.21 based on 2 Stage Free Cash Flow to Equity Anixa...
분석 기사 • Sep 12

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...
분석 기사 • May 23

We're Hopeful That Anixa Biosciences (NASDAQ:ANIX) Will Use Its Cash Wisely

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Jan 19

We're Not Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
분석 기사 • Oct 06

We Think Anixa Biosciences (NASDAQ:ANIX) Can Easily Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
분석 기사 • Apr 27

Is There An Opportunity With Anixa Biosciences, Inc.'s (NASDAQ:ANIX) 41% Undervaluation?

Key Insights The projected fair value for Anixa Biosciences is US$7.24 based on 2 Stage Free Cash Flow to Equity Anixa...
분석 기사 • Jan 13

Are Investors Undervaluing Anixa Biosciences, Inc. (NASDAQ:ANIX) By 36%?

Today we'll do a simple run through of a valuation method used to estimate the attractiveness of Anixa Biosciences...
분석 기사 • Sep 26

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 15

Anixa adds 11% after dosing initiation in CAR-T ovarian cancer trial

The shares of clinical-stage biotech Anixa Biosciences (NASDAQ:ANIX) jumped ~11% to reach the highest level since November on the announcement that the first patient received its chimeric antigen receptor T-cell (CAR-T) therapy in a Phase 1 clinical trial for ovarian cancer.   The dose escalation study conducted with its partner Moffitt Cancer Center is designed to assess the early efficacy data, safety and maximum tolerated dose of the follicle-stimulating hormone receptor T-cells. The trial is expected to enroll up to 48 patients at the Moffitt Cancer Center. Anixa’s (ANIX) CAR-T approach used in the study is known as chimeric endocrine receptor T-cell (CER-T) therapy. It differs from traditional CAR-T drugs in that it specifically targets the follicle-stimulating hormone receptor (FSHR) which, according to research, is exclusively located in ovarian cells of healthy adult women. In March, Anixa (ANIX) announced initial plans to conduct the trial.
Seeking Alpha • Jul 21

Anixa to get additional US patent linked to breast cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) said the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a new patent related to the company's breast cancer vaccine technology. The company said the technology has been exclusively licensed from and is being developed in partnership with Cleveland Clinic. The patent is titled 'Breast Cancer Vaccine' and the lead inventor is Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic's Lerner Research Institute. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin," said Anixa Chairman and CEO Amit Kumar.
분석 기사 • Jun 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Seeking Alpha • May 11

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times

Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably. Trial enrollment for the vaccine trial was fast, and the company seems optimistic about the near-term future of the company. The market is huge, and if the trial is successful, chances are we are seeing the beginning of a huge spike in share price. 2022 will, in any case, be the year for Anixa, with other programs ongoing as well.
분석 기사 • Feb 24

We're Interested To See How Anixa Biosciences (NASDAQ:ANIX) Uses Its Cash Hoard To Grow

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Oct 28

Companies Like Anixa Biosciences (NASDAQ:ANIX) Can Afford To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Anixa Biosciences...
Seeking Alpha • Sep 23

Our First Look At Anixa Biosciences

Today, we take an in-depth look at Anixa Biosciences, a small developmental firm on the west coast. The company's pipeline has multiple 'shots on goal' including one candidate that has shown some early analytical potential promise against the Covid-19 Delta variant. A full analysis is provided in the paragraphs below.
분석 기사 • Jun 12

Here's Why We're Not At All Concerned With Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
분석 기사 • Jan 13

Anixa Biosciences (NASDAQ:ANIX) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO 보수 분석

Amit Kumar의 보수는 Anixa Biosciences의 수익에 비해 어떻게 변했나요?
날짜총 보수급여회사 수익
Jan 31 2026n/an/a

-US$10m

Oct 31 2025US$3mUS$815k

-US$11m

Jul 31 2025n/an/a

-US$11m

Apr 30 2025n/an/a

-US$12m

Jan 31 2025n/an/a

-US$12m

Oct 31 2024US$3mUS$785k

-US$13m

Jul 31 2024n/an/a

-US$12m

Apr 30 2024n/an/a

-US$12m

Jan 31 2024n/an/a

-US$11m

Oct 31 2023US$4mUS$720k

-US$10m

Jul 31 2023n/an/a

-US$11m

Apr 30 2023n/an/a

-US$11m

Jan 31 2023n/an/a

-US$12m

Oct 31 2022US$2mUS$631k

-US$14m

Jul 31 2022n/an/a

-US$14m

Apr 30 2022n/an/a

-US$16m

Jan 31 2022n/an/a

-US$15m

Oct 31 2021US$11mUS$573k

-US$13m

Jul 31 2021n/an/a

-US$11m

Apr 30 2021n/an/a

-US$9m

Jan 31 2021n/an/a

-US$10m

Oct 31 2020US$2mUS$522k

-US$10m

Jul 31 2020n/an/a

-US$10m

Apr 30 2020n/an/a

-US$9m

Jan 31 2020n/an/a

-US$9m

Oct 31 2019US$665kUS$476k

-US$12m

보상 대 시장: Amit의 총 보수(USD2.55M)는 US 시장에서 비슷한 규모 기업의 평균(USD627.03K)보다 높습니다.

보상과 수익: Amit의 보상은 지난 1년 동안 회사 실적과 일치했습니다.

CEO

Amit Kumar (61 yo)

8.8yrs
재임 기간
US$2,546,684
보수

Dr. Amit Kumar, Ph.D. was a Director at Ascent Solar Technologies, Inc. since June 2007 until September 16, 2022 and had been its Independent Chairman of the Board since January 2011 until September 16, 20...

리더십 팀

이름직위재임 기간보수지분
Amit Kumar
CEO, Chairman & Co-Chair of CBAB8.8yrsUS$2.55m1.82%
$ 1.7m
Michael Catelani
President9.5yrsUS$1.30m0.13%
$ 124.2k
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board4.7yrs데이터 없음데이터 없음
8.8yrs
평균 재임 기간
61yo
평균 나이

경험이 풍부한 관리: ANIX의 경영진은 노련하고 경험이 풍부합니다(평균 재임 8.8 년).

이사회 구성원

이름직위재임 기간보수지분
Amit Kumar
CEO, Chairman & Co-Chair of CBAB13.5yrsUS$2.55m1.82%
$ 1.7m
Pamela Garzone
Chief Development Officer & Chair Breast Cancer Clinical Advisory Board3.3yrs데이터 없음데이터 없음
Lewis Titterton
Lead Independent Director8.8yrsUS$134.63k2.89%
$ 2.7m
H. Shepard
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Linda Kelley
Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Ian Frazer
Member of Scientific Advisory Board6.6yrs데이터 없음데이터 없음
G. Budd
Member of Breast Cancer Clinical Advisory Board3.3yrs데이터 없음데이터 없음
Arnold Baskies
Member of SAB & Breast Cancer Clinical Advisory Board7.7yrsUS$134.63k0.40%
$ 376.6k
Marco Davila
Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Jose Conejo-Garcia
Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Daniel Abate-Daga
Member of Scientific Advisory Board7.6yrs데이터 없음데이터 없음
Emily Gottschalk
Independent Director6.6yrsUS$134.63k0.14%
$ 127.4k
7.6yrs
평균 재임 기간
72yo
평균 나이

경험이 풍부한 이사회: ANIX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.6 년).

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/24 20:27
종가2026/05/22 00:00
수익2026/01/31
연간 수익2025/10/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Anixa Biosciences, Inc.는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Andrew D'SilvaB. Riley Securities, Inc.
Jason KolbertD. Boral Capital LLC.
Ilya ZubkovFreedom Broker